Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada begins human trial of respiratory drug
The trials will examine the product’s safety according to a plan approved by the European Agency for Evaluation of Medicinal Products. Kamada has also signed a strategic agreement
The trials will examine the product’s safety according to a plan approved by the European Agency for Evaluation of Medicinal Products. Kamada has also signed a strategic agreement
The FDA asked for clarification and additional interpretation regarding certain data included in the application to assist in its evaluation. Oscient submitted its response to the approvable letter
The acquisition could potentially strengthen the company's oncology focus across Europe. Sales of Nipent in Europe last year were almost $5 million, with France, Germany, Greece, Italy and
Further data showed the compound's good safety profile and established the maximum tolerated dose, which will be the recommended dose for a phase II trial. In addition to
Data from two phase III clinical studies that serve as the foundation for the new drug application demonstrated that Zingo provided statistically significant pain relief in children undergoing
The two companies believe that the agreement could make them significant market players in the oncology segment. The drug product is indicated for the treatment of advanced breast
The phase II trial will examine Davanat with Avastin, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced colorectal cancer who are unable to tolerate intensive chemotherapy with
According to Cenestra, Omax3 is the highest purity Omega 3 health supplement on the market, with each softgel containing 91% of pure Omega 3 content. The product is
“Since enrolling our first subject in September of this year, enrollment has proceeded rapidly, which we believe reflects the interest of our study investigators and clinicians in this
Biocon said that the drug could prove to be a multi-billion dollar opportunity for the company. “We are almost through with the phase II clinical trials of the